Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

NCT00230217 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors
Hyperuricemia
Tumor Lysis Syndrome

Interventions

DRUG: Rasburicase (SR29142)

Sponsor

Sanofi